PMID- 26700585
OWN - NLM
STAT- MEDLINE
DCOM- 20170904
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 32
IP  - 5
DP  - 2016 May
TI  - Network meta-analysis of treatments for type 2 diabetes mellitus following 
      failure with metformin plus sulfonylurea.
PG  - 807-16
LID - 10.1185/03007995.2015.1135110 [doi]
AB  - Aims The efficacy and safety of sodium-glucose linked transporters (SGLT2s) plus 
      metformin and a sulfonylurea (MET + SU) for the treatment of type 2 diabetes 
      mellitus (T2DM) in patients who fail to achieve glycemic control with MET + SU, 
      relative to other triple therapies licensed in the EU, were estimated. Methods A 
      systematic literature review and network meta-analysis (NMA) of randomized 
      controlled trials (RCTs) involving anti-diabetes treatments added to MET + SU 
      were conducted. RESULTS: Of 2236 abstracts identified through a systematic 
      literature review, 30 RCTs published between 2003 and 2013 were included. RCTs 
      ranged from 12 to 52 weeks in duration, included 28 to 1274 patients, were of 
      parallel design, and most were open-label. Comparators included placebo 
      (reference treatment), SGLT2 inhibitors, dipeptidyl peptidase-4 (DPP-4) 
      inhibitors, thiazolidinediones (TZDs), alpha-glucosidase inhibitors (AGIs), 
      meglitinides, glucagon-like peptide 1 (GLP-1) analogues, and basal, bolus, and 
      biphasic insulin, all added on to MET + SU, as well as basal and biphasic insulin 
      added to MET and monotherapy. The mean change (%) in HbA1c levels compared to 
      placebo was -0.86 for SGLT2 inhibitors, -0.68 for DPP-4 inhibitors, -0.93 for 
      TZDs, and -1.07 for GLP-1 analogues, respectively. Only SGLT2 inhibitors and 
      GLP-1 analogues led to a weight loss (-1.71 kg and -1.14 kg, respectively) and 
      decrease in systolic blood pressure (SBP; -3.73 mmHg and -2.90 mmHg, 
      respectively), while all other treatments showed either an increase or no changes 
      in weight or SBP. Conclusion SGLT2 inhibitors are at least as effective as other 
      classes of antidiabetic agents at controlling HbA1c levels, while providing the 
      additional benefits of weight loss and reducing SBP. Additionally, since the risk 
      of hypoglycemia is similar or reduced with SGLT2 inhibitors, patients do not have 
      to trade off efficacy for tolerability. Similar findings were observed for GLP-1 
      analogues.
FAU - Lozano-Ortega, G
AU  - Lozano-Ortega G
AD  - a Icon Epidemiology , Vancouver , Canada ;
FAU - Goring, S
AU  - Goring S
AD  - a Icon Epidemiology , Vancouver , Canada ;
FAU - Bennett, H A
AU  - Bennett HA
AD  - a Icon Epidemiology , Vancouver , Canada ;
FAU - Bergenheim, K
AU  - Bergenheim K
AD  - b AstraZeneca , Molndal , Sweden ;
FAU - Sternhufvud, C
AU  - Sternhufvud C
AD  - b AstraZeneca , Molndal , Sweden ;
FAU - Mukherjee, J
AU  - Mukherjee J
AD  - c Bristol-Myers Squibb , Wallingford , CT , USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160229
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemia/blood
MH  - Hypoglycemic Agents/*administration & dosage/therapeutic use
MH  - Metformin/therapeutic use
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Thiazolidinediones/therapeutic use
OTO - NOTNLM
OT  - Network meta-analysis
OT  - SGLT2 inhibitors
OT  - Triple therapy
OT  - Type 2 diabetes mellitus
EDAT- 2015/12/25 06:00
MHDA- 2017/09/05 06:00
CRDT- 2015/12/25 06:00
PHST- 2015/12/25 06:00 [entrez]
PHST- 2015/12/25 06:00 [pubmed]
PHST- 2017/09/05 06:00 [medline]
AID - 10.1185/03007995.2015.1135110 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2016 May;32(5):807-16. doi: 10.1185/03007995.2015.1135110. 
      Epub 2016 Feb 29.